117 related articles for article (PubMed ID: 19820024)
1. Pioglitazone treatment enlarges subcutaneous adipocytes in insulin-resistant patients.
Koenen TB; Tack CJ; Kroese JM; Hermus AR; Sweep FC; van der Laak J; Stalenhoef AF; de Graaf J; van Tits LJ; Stienstra R
J Clin Endocrinol Metab; 2009 Nov; 94(11):4453-7. PubMed ID: 19820024
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone improves insulin resistance and decreases blood pressure in adult patients with congenital adrenal hyperplasia.
Kroese JM; Mooij CF; van der Graaf M; Hermus AR; Tack CJ
Eur J Endocrinol; 2009 Dec; 161(6):887-94. PubMed ID: 19755409
[TBL] [Abstract][Full Text] [Related]
3. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
[TBL] [Abstract][Full Text] [Related]
4. Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study.
van Asseldonk EJ; Stienstra R; Koenen TB; Joosten LA; Netea MG; Tack CJ
J Clin Endocrinol Metab; 2011 Jul; 96(7):2119-26. PubMed ID: 21508140
[TBL] [Abstract][Full Text] [Related]
5. Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects.
Hammarstedt A; Sopasakis VR; Gogg S; Jansson PA; Smith U
Diabetologia; 2005 Jan; 48(1):96-104. PubMed ID: 15624096
[TBL] [Abstract][Full Text] [Related]
6. Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein β up-regulation.
Powell LA; Crowe P; Kankara C; McPeake J; McCance DR; Young IS; Trimble ER; McGinty A
Clin Sci (Lond); 2012 Aug; 123(3):135-46. PubMed ID: 22309242
[TBL] [Abstract][Full Text] [Related]
7. Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone.
Yao-Borengasser A; Varma V; Bodles AM; Rasouli N; Phanavanh B; Lee MJ; Starks T; Kern LM; Spencer HJ; Rashidi AA; McGehee RE; Fried SK; Kern PA
J Clin Endocrinol Metab; 2007 Jul; 92(7):2590-7. PubMed ID: 17595259
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone-induced increase of insulin sensitivity in the muscles of the obese Zucker fa/fa rat cannot be explained by local adipocyte differentiation.
Hallakou S; Foufelle F; Doaré L; Kergoat M; Ferré P
Diabetologia; 1998 Aug; 41(8):963-8. PubMed ID: 9726600
[TBL] [Abstract][Full Text] [Related]
9. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance.
de Souza CJ; Eckhardt M; Gagen K; Dong M; Chen W; Laurent D; Burkey BF
Diabetes; 2001 Aug; 50(8):1863-71. PubMed ID: 11473050
[TBL] [Abstract][Full Text] [Related]
10. Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle.
Li W; Tonelli J; Kishore P; Owen R; Goodman E; Scherer PE; Hawkins M
Am J Physiol Endocrinol Metab; 2007 May; 292(5):E1301-7. PubMed ID: 17213476
[TBL] [Abstract][Full Text] [Related]
11. Effect of pioglitazone on insulin sensitivity, vascular function and cardiovascular inflammatory markers in insulin-resistant non-diabetic Asian Indians.
Raji A; Gerhard-Herman MD; Williams JS; O'connor ME; Simonson DC
Diabet Med; 2006 May; 23(5):537-43. PubMed ID: 16681563
[TBL] [Abstract][Full Text] [Related]
12. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.
Wallace TM; Levy JC; Matthews DR
Diabet Med; 2004 Jun; 21(6):568-76. PubMed ID: 15154941
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase-9 is increased in obese subjects and decreases in response to pioglitazone.
Unal R; Yao-Borengasser A; Varma V; Rasouli N; Labbate C; Kern PA; Ranganathan G
J Clin Endocrinol Metab; 2010 Jun; 95(6):2993-3001. PubMed ID: 20392866
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
Ciaraldi TP; Aroda V; Mudaliar SR; Henry RR
Metabolism; 2013 Nov; 62(11):1587-96. PubMed ID: 23958241
[TBL] [Abstract][Full Text] [Related]
15. Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.
Minoura H; Takeshita S; Kimura C; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Mutoh S
Diabetes Obes Metab; 2007 May; 9(3):369-78. PubMed ID: 17391165
[TBL] [Abstract][Full Text] [Related]
16. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
[TBL] [Abstract][Full Text] [Related]
17. Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type II from free fatty acid-induced insulin resistance.
Serlie MJ; Allick G; Groener JE; Ackermans MT; Heijligenberg R; Voermans BC; Aerts JM; Meijer AJ; Sauerwein HP
J Clin Endocrinol Metab; 2007 Jan; 92(1):166-71. PubMed ID: 17062758
[TBL] [Abstract][Full Text] [Related]
18. High circulating levels of RBP4 and mRNA levels of aP2, PGC-1alpha and UCP-2 predict improvement in insulin sensitivity following pioglitazone treatment of drug-naïve type 2 diabetic subjects.
Hammarstedt A; Pihlajamäki J; Graham TE; Kainulainen S; Kahn BB; Laakso M; Smith U
J Intern Med; 2008 Apr; 263(4):440-9. PubMed ID: 18324929
[TBL] [Abstract][Full Text] [Related]
19. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
20. The effect of pioglitazone on the liver: role of adiponectin.
Gastaldelli A; Miyazaki Y; Mahankali A; Berria R; Pettiti M; Buzzigoli E; Ferrannini E; DeFronzo RA
Diabetes Care; 2006 Oct; 29(10):2275-81. PubMed ID: 17003306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
